BAM
RNTX

Brave Asset Management’s Rein Therapeutics RNTX Stock Holding History

Brave Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-833
Closed -$32K – 171
2019
Q1 		$32K Sell
833
-300
-26% -$9.35K 0.02% 148
2018
Q4 		$19K Buy
1,133
+383
+51% +$15.4K 0.01% 145
2018
Q3 		$41K Buy
+750
New +$50.5K 0.02% 145

Other funds holding RNTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Brave Asset Management's RNTX Position: Q2 2019 in Review

Brave Asset Management sold out of Rein Therapeutics (RNTX) in Q2 2019, closing a stake of 833 shares — an estimated $32K sold.

Brave Asset Management first reported a position in RNTX in Q3 2018 and held it in 3 quarters. The position peaked at $41K in Q3 2018. 22 funds tracked by Wall St. Rank hold RNTX as of Q2 2019.

  • Brave Asset Management reported no remaining Rein Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Brave Asset Management sold 833 Rein Therapeutics shares in Q2 2019, an estimated $32K.
  • Brave Asset Management first reported a position in Rein Therapeutics in Q3 2018 and held it in 3 quarters.
  • Brave Asset Management's Rein Therapeutics position peaked at $41K in Q3 2018.
  • 22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2019.

Based on Brave Asset Management's 13F filing for Q2 2019, filed 5 Aug 2019.